Hims & Hers Health lowered its 2026 profit forecast for the third time this year after reporting a surprise $33 million quarterly loss. Revenue grew 49% to $890.4 million, but gross margin dropped due to a shift toward lower-margin weight-loss drugs. The company deliberately reduced U.S. weight-loss marketing, causing a 100,000 subscriber decline, which CEO Andrew Dudum called a trade-off for long-term growth. Despite the profit cuts, the company remains cash-positive with $710 million on hand. Investors will watch the fourth-quarter report in February for updates on 2027 outlook and growth investments.
As of Nov 10, 2026 19:42 WIB, Hims & Hers Health Inc (HIMS) shares trade at USD 22.80 on Pluang, down 0.61% for the day with a market cap of $5.35 billion. Despite the recent profit warnings and subscriber losses, Pluang investors show strong buying interest with 100% buy order activity. The stock's enterprise value stands at $6.06 billion, reflecting ongoing market attention to the company's strategic shifts and financial position.
Anthropic, the AI company behind Claude, is set to begin trading next week after ending its 15-day waiting period post-S-1 filing. The company aims to raise $80B-$100B with a valuation between $1.25T and $1.75T, potentially making it the largest IPO ...
The Health & Wellness Power Hour program encourages participants to start their mornings with small, manageable actions that build momentum over 21 days. This approach helps individuals establish a productive morning routine by focusing on incrementa...
Hims & Hers Health has struck a deal with Eli Lilly allowing patients to buy Lilly's GLP-1 medications, including the popular Zepbound injection and Foundayo pill, directly through Hims & Hers' telehealth platform. Previously, patients had to use Lil...
Hims & Hers Health announced a partnership with Eli Lilly to offer Eli Lilly's GLP-1 drugs through its platform, providing a significant boost to the company's stock. This agreement is seen as a much-needed positive development for Hims & Hers, poten...
